- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Atrimed Pharma to introduce plant-based drug for COVID-19 treatment
![Atrimed Pharma to introduce plant-based drug for COVID-19 treatment Atrimed Pharma to introduce plant-based drug for COVID-19 treatment](https://medicaldialogues.in/h-upload/2020/03/05/750x450_125232-coronavirus-15.webp)
Bangalore: Bangalore based Atrimed Pharmaceuticals announced that three of its samples tested positive against SARS-CoV-2 in the ICMR (Indian Council for Medical Research) designated laboratory and the developed drug will be available as oral medicine.
Company Leverages Proven Antiviral and Plant-based medicinal expertise to evaluate the new approaches for treating the Novel Coronavirus Disease COVID-19. Atrimed Pharma is dedicated to developing Phyto molecule drugs for viral infections and other diseases, today takes pride that it has initiated a program to discover drug candidates for the treatment of patients infected with the novel coronavirus COVID-19, also known as SARS-CoV-2.
Commenting on the exclusive breakthrough Dr Hrishikesh Damle MD & CEO stated, "Based on our proven track record in virology and our capabilities in rare diseases, we believe our core competencies position us well to discover a potential treatment for COVID-19, and we are delighted to establish that three molecules out of ten submitted are passed the test and ready for Human/Clinical Trial for developing a drug for the treatment of Coronavirus."
He further added that these molecules were ready for scientific research in the month of March 2020 itself but took so long for clearance. "Our decision to initiate a drug discovery for COVID-19 is a natural evolution of our work and mission. Regional Centre for Biotechnology has recognized and approved 3 effective plant molecules against COVID-19 and further studies will begin shortly."
The Drug Discovery and Development Process passes through various stages which begins with Target Selection leading to discovery wherein high throughput screening paves for chemical synthesis and then prepares for Vitro/Behavioural Studies and finally for Clinical/Human trial, and it is a great achievement for Atrimed to take their research to their drug development to the next level.
Based in Bangalore, Atrimed Pharma develops medicines from plant-based molecules to develop drugs that cure diseases that have plagued humanity such as Psoriasis, Acne, Arthritis, and more. It combines the traditional cures with the knowledge base created from computer-aided drug design, biotechnology and Artificial Intelligence to establish a library of plant molecules, some 400,000 strong, the largest in the world. Its products cater to Skin and Haircare, Mother and Child care, and Bone related diseases, Nutrition, Metabolism and Allergies.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751